Insights on Covid ‐19 with superimposed pulmonary histoplasmosis: The possible nexus
Pulmonary histoplasmosis may occur in Covid-19 patients; therefore, immune dysregulation chiefly lymphopenia in Covid-19 may increase the risk for the progress of pulmonary histoplasmosis. As well, the activation of inflammatory signaling pathways during H. Capsulatum infection may increase the severity of Covid-19 and vice versa. AbstractA novel coronavirus (CoV) known as severe acute respiratory syndrome CoV type 2 is the causative agent for the development of CoV disease 2019 (Covid-19). Covid-19 may increase the risk of developing pulmonary histoplasmosis due to immune dysregulation. In addition, Covid-19 may enhance the propagation of acute pulmonary histoplasmosis due to lung injury and inflammation, and using corticosteroids in severely affected Covid-19 patients may reactivate latent pulmonary histoplasmosis. Likewise, activation of inflammatory signaling pathways duringH. capsulatum infection may increase the severity of Covid-19 and vice versa. Furthermore, lymphopenia in Covid-19 may increase the risk for the progress of pulmonary histoplasmosis besides activation of inflammatory signaling pathways duringH. capsulatum infection may increase the severity of Covid-19 and vice versa. Therefore, this critical review aimed to find the potential link between Covid-19 pneumonia and pulmonary histoplasmosis concerning the immunological response.
Source: Immunity, Inflammation and Disease - Category: Allergy & Immunology Authors: Yahya A. Almutawif,
Hayder M. Al ‐kuraishy,
Ali I. Al‐Gareeb,
Athanasios Alexiou,
Marios Papadakis,
Hamza M. A. Eid,
Hebatallah M. Saad,
Gaber El‐Saber Batiha Tags: REVIEW ARTICLE Source Type: research
More News: Allergy & Immunology | Coronavirus | Corticosteroid Therapy | COVID-19 | Pneumonia | Respiratory Medicine | SARS